KHEIRON
MEDICAL TECHNOLOGIES

AI for Breast Cancer Screening

Dr. Peter Kecskemethy, co-founder and CEO

Breast Cancer Screening - Intro

KHEIRON MEDICAL TECHNOLOGIES

Screening

Small subsidised up-front cost

Early Detection

Low-cost high-profit surgeries,
Less expensive chemo
Better outcomes

Screening works!

up to **80%** of cancers are detected

~70% early stage

With 70% attendance:

56% of all BCs are caught earlier in screening

40% at stage I-II when surgery is enough

Breast Cancer Screening - Intro

KHEIRON MEDICAL TECHNOLOGIES

Screening

Small subsidised up-front cost

Early Detection

Low-cost high-profit surgeries,
Less expensive chemo
Better outcomes

Screening works!

up to **80%** of cancers are detected

~70% early stage

With 70% attendance:

56% of all BCs are caught earlier in screening

40% at stage I-II when surgery is enough

Breast Cancer Screening - Problems

KHEIRON MEDICAL TECHNOLOGIES



AI in Breast Cancer Screening - Opportunities

KHEIRON MEDICAL TECHNOLOGIES

Mia™ Suite



Missed cancers ↓

False alarms ↓

Direct Costs ↓

Patient Experience ↑

Patient Outcomes ↑

AI in Breast Cancer Screening - Status

KHEIRON MEDICAL TECHNOLOGIES

Tested on 350k+ cases, deploying in 25% of NHS

Outcomes from live operation of Mia XR

26 extra proven cancers detected that doctors missed
- All **26** cancers were missed by 2 doctors
- Most worked up cancers are proven **invasive**

In the first pilot, every recalled woman had cancer, i.e. had zero false positives from the XR workflow

The New York Times

Using A.I. to Detect Breast Cancer That Doctors Miss

THE TIMES THE SUNDAY TIMES

TECH SUMMIT

AI is transforming how radiologists detect breast cancers

Kheiron Medical Technologies has developed deep-learning software to act as as second reader of mammograms

nature medicine

THE TIMES

HEALTHTECH

Mammogram-reading AI starts work in hospitals

Impact opportunity

- ✓ Up to **13-20% more cancers detected** (up to +1.6 CDR)
- ✓ Possible **50% reduction of missed cancers**
- ✓ Possible **zero unnecessary recalls**

AI in Breast Cancer Screening - Economic Impact

KHEIRON MEDICAL TECHNOLOGIES

"Back of the envelope" calculation assuming

50% miss reduction w/ AI
70% attendance

63% of all BCs caught early

75% miss reduction w/ AI
75% attendance

71% of all BCs caught early

(compared to 56% without AI)

AI Beyond Breast Cancer Screening

KHEIRON MEDICAL TECHNOLOGIES

Reliable response evaluation

Precision response evaluation

Data-driven multi-disciplinary diagnostics

- Radiology
- Blood markers
- Genetics
- Pathology

Precision treatment planning